New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:06 EDTTBIOTransgenomic Inc announces issuance of U.S. patent for ICE COLD-PCR
Transgenomic announced that the U.S. Patent and Trademark Office has issued a new patent related to its licensed ICE COLD-PCR technology. The patent, titled “Full cold-PCR enrichment with reference blocking sequence”, was assigned U.S. Patent No. 8,623,603 and is set to expire in 2031. The new U.S. patent extends the scope and longevity of the COLD-PCR intellectual property portfolio. The '603 patent covers ICE COLD-PCR methods for enriching low abundance alleles in nucleic acid samples. It is directed in particular to the use of an excess amount of reference blocking sequence in an amplification reaction mixture in order to improve the enrichment efficiency, and reduce cycle time, of full COLD-PCR.
News For TBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 22, 2015
07:06 EDTTBIOTransgenomic plans to launch six new genetic cancer tests this year
Transgenomic announced that it is planning to launch up to six new genetic cancer tests this year based on its Multiplexed ICE COLD-PCR, or MX-ICP, technology. The new tests will focus on actionable genetic mutations and alterations in patients with melanoma, non-small cell lung cancer, or NSCLC, and colorectal cancer, and will include both single tests and multi-gene panels. Transgenomic’s MX-ICP technology has demonstrated exceptional sensitivity and accuracy using either standard tissue or liquid biopsy samples such as blood and plasma. The tests are expected to be available for diagnostic use through Transgenomic’s CLIA-certified laboratory. “We are ahead of schedule in commercializing our pipeline of laboratory-based cancer tests to meet the growing demand for targeted and personalized cancer treatments,” said Paul Kinnon, president and CEO of Transgenomic. “The unsurpassed accuracy of our Multiplexed ICE COLD-PCR technology and its ability to produce highly sensitive and accurate results from small amounts of virtually any type of patient sample enable its broad use for tumor detection and monitoring. The fact that MX-ICP is a platform technology is also facilitating the rapid development of our pipeline. We intend to release two or three new single and panel tests per quarter for the remainder of this year, focusing on the two most prevalent cancers--colorectal and lung, as well as melanoma, which is especially amenable to targeted therapies.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use